Annual Review
2022









cancer trials ireland

Together, we're finding answers to cancer.

Supported by

Irish Cancer Society

HRB Health Research Board

What we do

Since Cancer Trials Ireland was established in 1996, more than 15,000 patients have participated in over 350 of its trials. Almost all cancer treating specialists in Ireland are members of Cancer Trials Ireland.

The organisation's trials are carried out in 14 hospital-based Cancer Trials Units (CTUs) across the country, supported by a central team of clinical researchers, project managers, data managers and other experts. As well as managing its own investigator-led trials, Cancer Trials Ireland also works with global pharmaceutical companies and international collaborative research groups, which generates substantial inward investment and access to innovative treatments for cancer patients.

Cancer is a global health issue. The World Health Organisation reports that cancer is the second leading cause of death globally and is responsible for an estimated 9.6 million deaths in 2018. Globally, about 1 in 6 deaths is due to cancer.

According to the 2019 Annual Report from the National Cancer Registry of Ireland (NCRI), cancer is the most common cause of death in Ireland, accounting for almost 31% of deaths in 2016. The approximate annual average of deaths from invasive cancer occurred from 2014-2016 and was 9,020. It is estimated that about 35,440 invasive cancers were diagnosed annually in 2017, 2018 and 2019 in Ireland.

Taking the ageing population into account, NCRI projections (2019) show cancer rates have stabilised or even declined in recent years. Nevertheless, projected population growth and ageing in Ireland will result in a substantial increase in the number of cancer cases in the coming decades, potentially doubling from current levels by 2045.

Vision & Mission

The Board rotates at the AGM every year as per the Constitution. The Board is chaired by Deirdre Somers, appointed in 2021.

The Cancer Trials Ireland Board of Directors consulted widely with staff, stakeholders and members before setting the strategy in 2022.

The vision is to be an indispensable, all-Island, hub for cancer trials, globally recognised for excellence in governance, collaboration, and innovation in clinical research. The mission and purpose of the company is to maximise cancer trial access and outcome to prolong patient lives, and expand cancer research, in Ireland.

The values of Cancer Trials Ireland are core to driving our purpose; they guide actions and behaviours of the team. The following values inform the culture at Cancer Trials Ireland;

- ***Trusted*** by clinicians, patients, researchers, and funders
- ***Empathetic***: to our patients' need and vulnerability
- ***Collaborative***: with researchers, clinicians, decision makers and our teams
- ***Ambitious***: to find, sponsor and operate the highest quality cancer trials for Ireland
- ***Accountable and transparent***: in everything that we do
- ***Ethical and professional***: in achieving our goals
- ***Determined***: in achieving our vision

Cancer Trials Ireland has 5 Key Strategic Objectives (KSOs) for 2022-2026.

1. Maximise contribution to National Cancer Strategy
2. Optimal, stable, and scalable talent to serve growth
3. Position clinical research as an integral part of cancer care through thought leadership, advocacy, and influence
4. Deliver a compelling "All-Island" cancer trial proposition.
5. Financially sustainable and funded for growth.

Published by Cancer Trials Ireland
Charity No. CHY12492
Royal College of Surgeons, Ireland
RCSI House, 121 St. Stephen's Green, Dublin 2, D02 H903
Ireland
Tel: +353 (0)1 6677211

2022 at a glance

In 2022, 8% of the enrolling trials were Investigator-Led Trials (ILTs) (2021: 8%) funded by the grants received from the Health Research Board and the Irish Cancer Society. 33% (2020: 29%) of these open trials involved collaboration with cancer research groups and/or were Investigator-Led Trials which are funded through pharmaceutical companies. The 59% balance (2021: 63%) of open trials are run by international pharmaceutical companies in Irish hospitals (2021: 63%) where staff at the General Central Office do limited work and receive little or no support. However, to capture a complete picture of cancer clinical trials in Ireland, we adopt these trials into our portfolio. During 2022, the 11 hospital based cancer trials research units were working on 302 active cancer trials (including trials in follow-up). All these trials involved a highly cooperative effort between investigators, research teams in each hospital based research unit and the staff at our central office.

Of the 97 trials that were open and recruiting patients during 2022:

- 8% were **Investigator-Led Trials** (which Cancer Trials Ireland initiates, manages, sponsors and monitors) and are generally funded by the grants received from the Health Research Board (HRB), and the Irish Cancer Society or pharmaceutical companies.
- 33% were **Collaborative** trials which involve working closely with other cancer research groups around the world.
- 59% were **Industry** trials which were initiated and managed by pharmaceutical companies and adopted into our trials portfolio.




Fig 1: % of Enrolling trials which were ILTs, Collaborative and Industry trials.

There were 32 articles published in peer-reviewed journals and 16 oral and poster abstract conference presentations based on the findings of trials in which Members of Cancer Trials Ireland are, or have been, involved.

We were involved in 87 collaborations with pharmaceutical companies, collaborative groups and universities around the world.

Cancer Trials Ireland total membership on 31st December 2022 was 635. (79 new members joined during 2022). During 2022 there were 229 Stakeholder members.

Chairperson's message



Deirdre Somers

I am delighted to introduce our Annual Review for 2022. At the start of 2022, the Board and Leadership Team met for an invigorating strategy workshop. This was the cornerstone of the development of a 5-year Strategic Plan. The mission and vision are clear, we seek to be an indispensable all-Ireland hub for cancer trials and maximise cancer trial access.

Five key objectives are set to be implemented by the organisation over the coming years;

1. Maximise contribution to National Cancer Strategy
2. Optimal, stable, and scalable talent to serve growth
3. Position clinical research as an integral part of cancer care through thought leadership, advocacy, and influence
4. Deliver a compelling "All-Island" cancer trial proposition.
5. Financially sustainable and funded for growth.

Key partnerships with the Irish Cancer Society and the Health Research Board continue to grow, and they facilitate our ability to deliver our strategy and more opportunities for Irish patients. A massive vote of thanks to all our staff and the network of physicians, nurses and site staff who worked hard to get our trials up and running. Also, I wish to mention my colleagues on the Board of Cancer Trials Ireland. They have continually demonstrated a huge level of commitment and have overseen a significant improvement in the organization's governance at Board level and through Board subcommittees. After a successful 2022 we are looking forward with optimism for the years ahead.

Our Board

The Board rotates at the AGM every year as per the Constitution. The Board is chaired by Deirdre Somers, appointed in 2021 and she is a strategy and governance expert. The Board meets 5 times per year and permanent agenda items include reports from Clinical Executive Committee and Audit Committee, Governance, Strategy, Conflict of Interest Declarations and Finance. In 2022, the Board met five times. (2021: 5)

The members of the Board are qualified to hold their position and represent a range of skills; governance, patient advocate, clinical oncologists, radiation oncologists, industry representative, finance and National Cancer and Control Programme (NCCP) representative. In 2018 the Board appointed a new subgroup called the Patient Consultant's Committee (PCC) set up to integrate the patient voice and experience in the governance structure of the organization.

The Clinical Executive Committee (CEC), Scientific Management Group and Disease Specific Sub-Groups monitor progress on the ongoing clinical trials, make decisions on the adoption of new trials to the portfolio and the CEC reports to the Board of Directors through its Chair; Prof. Ray McDermott, Clinical Lead.

The Audit Committee is a subcommittee of the Board and was established in the summer of 2016 and met 8 times in 2022. Darren Byrne is the chair of the Audit Committee and member of the Board of Directors.

- Deirdre Somers (Chair)
- Darren Byrne
- Dr Ruth Barrington
- Dr Jerome Coffey
- Rory Montgomery
- Paula Murphy
- Prof Seamus O'Reilly
- Patrick Kivlehan
- Conor King
- Prof Michael John Kennedy
- Sharon McCabe

Secretary: David Donovan

How we are organised

Chairperson & Board of Directors

Committees of the Board

Audit & Risk Committee

Met 8 times in 2022. Chair: Board Member Darren Byrne.

Clinical Executive Committee

Meets 5 times in 2022. Chair: Prof Ray McDermott, Clinical Lead.

Nominations & Governance Committee: 3 meetings

Patient Consultants Committee: 5 meetings in 2022

SMG - Scientific Management Group

Meets 3 times a year. Chair: Prof Seamus O'Reilly, Vice Clinical Lead. The work of the SMG is informed by the Disease Specific Sub Groups (DSSG) which meet 3 times a year, and are in turn informed by the 500+ Membership.

External Advisory Board Convened as required.

Clinical Oversight

Prof Ray McDermott, Clinical Lead.

Prof Seamus O'Reilly, Vice Clinical Lead.

Location of hospital based Cancer Trials Research Units

Letterkenny University Hospital
Sligo University Hospital
University Hospital Galway
University Hospital Limerick
Cork University Hospital
Bon Secours, Cork
Midland Regional Hospital Tullamore
University Hospital Waterford
Beaumont Hospital
Mater Misericordiae University Hospital
St James's Hospital
Tallaght Hospital
St Luke's Radiation Oncology Network
St Vincent's University Hospital
Beacon Hospital
Childrens Health Ireland, Crumlin

CEO and Central Office Team

Manages Cancer Trials Ireland's trials monitoring and business functions; clinical project management, pharmacovigilance, data management, on-site monitoring, quality management and training.

The team co-ordinates the activities of the Disease Specific Sub-Groups (DSSGs) through which the research portfolio is developed.

It provides local expertise in regulatory and ethics processes in Ireland, the UK and Europe as well as Pharmacovigilance - trained employees in this area who have direct access to the European safety database (Eudravigilance) for safety reporting purposes according to regulatory requirements.

The central office team has experience in drug distribution, accountability and labelling, which has facilitated our work with industry and our collaboration with international partners.

From our CEO



Eibhlín Mulroe

With one final move within the RCSI St Stephen's Green campus in 2022, Cancer Trials Ireland settled into our final home, in RCSI House. The modern, refurbished office and attractive, central location are a great match for our more stable hybrid workforce, in the aftermath of the pandemic.

The strategic objectives set by the Board in 2022 were introduced to our members and community at the second Cancer Retreat, in May. In June, a staff strategy workshop explored the objectives in detail, in line with our second objective on 'Optimal, Stable & Scalable Talent'.

The Cancer Retreat spoke to Strategic Objective #3 (positioning clinical research as a part of cancer care) by focusing on the barriers to patient accrual to trials, but also celebrating trial successes, such as CLL17, the PACE-C trial. The Retreat also featured an introductory message from the Acting head of the National Cancer Institute, in USA, Dr Doug Lowy.

I look forward to updating you on progress across all five of our strategic objectives in due course. Until then, I want to thank our Chair and Board for their expertise, support and guidance through some challenging transitions, and I look forward to leveraging their energy and abilities in the coming year. In closing I must thank the team at our office and at sites, their intelligence and commitment to cancer research make this place the best working environment. We have a great purpose, bringing hope to our cancer patients.

From our Clinical Lead



Prof Ray McDermott

As the 2022 Just Ask campaign celebrating International Clinical Trials Day revealed, public support for clinical trials is high, and climbing. Three in five people said they would be willing to take part in a clinical trial. 85% agree – and 44% strongly agree – that trials provide access to treatments not otherwise available, and 78% agreed that the COVID19 pandemic highlighted the importance of clinical trials. Regrettably, this degree of understanding and appreciation is not reflected in the resourcing and structures that currently exist for cancer clinical trials in Ireland.

If Ireland is ever to level up as a world class location / destination for clinical research, we need to dramatically speed up the time it takes to open trials. Some improvements have been made in the research ethics environment, but these gains are offset by delays associated with the uncertain and fragmented implementation of GDPR. The system must resource research governance, and employ fulltime Data Protection Officers, and research governance officers, to streamline and harmonise the data protection documents hindering clinical trials in Ireland right now.

This is by no means the only problem facing the progression of clinical oncology research in Ireland, but it is one that affects everyone involved – not just, or only, the investigators, but the research nurses, data managers, project managers, and the patients themselves. We will continue to highlight and advocate around this persistent problem.

Finally, I wish to thank my colleague Prof Seamus O'Reilly, Vice-Clinical Lead for Cancer Trials Ireland, and also my colleagues who chair the DSSGs.

Achievements & Performance 2022

- Cancer Trials Ireland began year 1 of the 5-year Health Research Board Cancer Trials Network with the RCSI as the Host Institution. The grant will award €6.9m over 5 years from January 2022 to Cancer Trials Ireland.
- In 2022, 97 trials in the CTRIAL portfolio were open to patient accrual. Of these 8% were Investigator Led Studies (2021: 8%) and 33% (2021: 31%) were collaborative group trials, which involve collaboration with other collaborative groups in EU and globally. The 59% (2021: 61%) balance of open trials are run by international pharmaceutical companies in Irish hospitals.
- Strong recruitment to collaborative group interventional trials continued during 2022 such as the CLL 17 trial in the lymphoma and haematology (blood cancers) portfolio which in Ireland alone recruited 86 patients out of a total of 900 globally, 42 of those during 2022. The investigator-led trials in the lymphoma and haematology (blood cancers) portfolio also performed very well with 13 of a total 18 required patient accruals to the CPD-DARA trial and 16 to the ISA-RVD trial which is still ongoing and will recruit a total 50 patients through 2023 and into 2024. A total of 15 patients were enrolled during 22 in the DASL-HiCAP study, an international collaborative group trial (ANZUP) in prostate cancer sponsored by Cancer Trials Ireland in Ireland and the UK, while 24 patients were enrolled in the IRONMAN Registry, another international collaborative study in prostate cancer. Other disease areas which saw steady accrual were in breast cancer – a collaborative group study (SASCIA) - and a radiotherapy investigator-led trial (SOURCE Lung).
- As part of the Just Ask campaign, a hybrid (in-person & virtual) Cancer Retreat was held for a second year in 2022. The event also involved the NCI's Acting Director, representatives of HSE NCCP, HRB, Irish Cancer Society, seven leading oncologists & haematologists and members of industry, with 263 registered attendees from the cancer trials community in Ireland.
- Cancer Trials Ireland hosted two stakeholders' events on DSSG meeting days, addressing 1) Cancer Trials & Data Protection and 2) Public & Patient Involvement.
- Cancer Trials Ireland CEO addressed the Joint Oireachtas Committee for the Implementation of the Good Friday Agreement (November) as part of the All-Island Cancer Research Institute delegation.
- Prof. Seamus O'Reilly, of Cancer Trials Ireland's Clinical Leadership, published a peer-reviewed paper entitled "The SARS-CoV-2 Pandemic and Cancer Trials Ireland: Impact, Resolution and Legacy (https://pubmed.ncbi.nlm.nih.gov/35565375/)".
- Cancer Trials Ireland facilitated regular Stakeholder Engagement and Patient Consultant Committee (PCC) meetings in 2022 and appointed a PPI Co-ordinator in October 2022.
- Philanthropy in 2022 was strong with the Property Picnic (€170,000+), the Pat Smullen Race Day at the Curragh (see below), the Friends of Cancer Trials Ireland (€141,000+), in addition to smaller sums raised by groups and individuals throughout the year. Significantly, the breast study SHAMROCK is funded by a €1m donation via Breast Cancer Ireland.
- The Pat Smullen Fund committee continued to meet with friends of Pat in 2022 to oversee the spending of funds and take advice on future projects. In August, the Pat Smullen Race Day at the Curragh (including the Coast to Curragh cycle) raised €165,000+ for pancreatic research.
- Cancer Trials Ireland organised three Clinical Trials Unit staff meetings (Team Leaders) and one workshop with the CEO, Quality and Comms to look at how best to support the units and streamline cancer trials.


Performance metrics

- **In line with best practice among similar international collaborative research groups, we use a series of recognised metrics to measure our performance.**
- **Our performance against these metrics is outlined on pages 9 to23.**

No	Performance Metric	Explanation
1	Accrual	Refers to the number of patients recruited to a trial.
2	Trials portfolio	The number and type of trials in our portfolio.
3	Collaborations	The organisations Cancer Trials Ireland works with on trials
4	Training	The number of training courses conducted and attended.
5	Cancer trials research unit monitoring	Monitoring activity of cancer trials research units includes a broad range of activities conducted from trial commencement until close-out.
6	Pharmacovigilance	Serious Adverse Events (SAEs), Suspected unexpected Serious Adverse Events (SUSARs)
7	Participation	Attendances at scientific meetings, International Meetings
8	Publications	The number of publications in peer-reviewed journals and abstracts accepted at top level international.

Accruals: Interventional Trials (Drug / Radiotherapy / Medical Device) By Disease area (percentage)

This metrics records the number of patients accrued to Interventional Trials by Disease Area




By disease area (accrual numbers)

Disease area	2022
Basket	28
Breast	89
GI	11
GU	63
Gynae	4
Lung	23
Lymph & Haem	106
Melanoma	6
Paeds	5
Total	**335**

Accruals: Non-Interventional Trials (Biobank / Observational / Registries / Translational) By Disease area (percentage)

- This metrics records the number of patients accrued to **Non-Interventional Trials by Disease Area**

By disease area (percentage)



By disease area (accrual numbers)

Disease Area	2022
Breast	424
Genito-urinary	24
Lung	19
Lymphoma & Haematology	167
Paediatric	15
Total	**649**

Trials portfolio

This metric records the number and type of trials open and in development during 2022. In-house trials and Collaborative trials (which involve research organisations in other countries) were an important area of focus during 2022. Both In-house trials (which are funded by either HRB, Irish Cancer Society and other supports and/or directly by pharmaceutical companies) and Collaborative trials, are fully supported by our central office clinical, professional, operations and administrative teams. The third type of trials included in our portfolio are Industry trials. While these trials are carried out in the various cancer trials research units, central office staff are minimally involved.

Table 1

Disease Area	2018	2019	2020	2021	2022
Basket	6	5	9	9	10
Breast	54	57	45	47	44
CNS	5	5	5	5	4
Gastro-intestinal	43	40	31	31	30
Genito-urinary	44	46	42	46	44
Gynaecology	13	16	14	15	20
Head & Neck	9	11	11	10	10
Lung	36	34	30	32	33
Lymphoma & Haematology	27	31	30	45	45
Melanoma	10	12	8	8	8
Paeds	40	38	43	42	40
Total No of active trials	**287**	**295**	**268**	**290**	**288**

Table 1 shows the total number of trials active in a particular disease group. 'Active' means trials in development, open, in treatment, in follow-up.

Table 2

Disease Area	2018	2019	2020	2021	2022
Basket	4	4	7	4	5
Breast	14	13	13	13	10
CNS	1	2	2	5	0
Gastro-intestinal	8	10	14	12	7
Genito-urinary	16	12	13	17	9
Gynaecology	5	7	8	6	4
Head & Neck	4	0	2	3	3
Lung	13	10	5	9	9
Lymphoma & Haematology	7	6	7	14	15
Melanoma	3	0	2	3	4
Paeds	26	26	22	19	20
Total No of accruing trials	**101**	**90**	**95**	**105**	**86**

Table 2 shows the total number of trials open to accrual only.

Collaborations with international research groups

A large part of the 2022 portfolio of studies in development, open and in follow up studies originate from successful collaborations with international groups.

- **ABCSG -** Austrian Breast and Colorectal Cancer Study Group
- **AIEOP (Italy) -** Associazone Italiana di Ematologia e Oncologia
- **ANZUP -** The Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group
- **BC Cancer -** British Columbia cancer
- **BIG -** Breast International Group
- **Bristol Royal Hospital**
- **CCTG -** Canadian Cancer Trials Group
- **CRUK** - Cancer Research UK
- **CCRI (Austria) –** St Anna Children's Cancer research Institute
- **Children's Cancer Research Institute Vienna (Austria)**
- **COG** – Children's Oncology Group
- **DCOG –** Dutch Childhood Oncology Group
- **DSCLL –** Deutsche Studiengruppe CLL
- **Dutch Collaborative Group**
- **ECOG - ACRIN** (Eastern Cooperative Oncology) and ACRIN (American College of Radiology Imaging Network) Research Group
- **ENGOT / NOGGOG**—The European Network for Gynaecological Oncological Trial groups
- **EORTC**—European Organisation for Research and Treatment of Cancer
- **Erasmus Medical Centre**
- **ETOP**—European Thoracic Oncology Platform
- **European Rhabdoid Registry**
- **Fondazione IRCCS Istituto Nazionale Tumori, Milano**
- **Fondazione Michelangelo**
- **Fundacion Para la Investigacion Hospital Universitario La Fe**
- **GBG** - German Breast Group
- **GCIG –** Gynaecologic Cancer intergroup
- **GEICAM** - Grupo Español de Investigación en Cáncer de Mama
- **GERCOR** - Groupe Coopérateur Multidisciplinaire en Oncologie
- **GOSH (UK) –** Great Ormond Street Hospital
- **Gustave Roussy Cancer Campus Paris**
- **HOPP Children's Cancer Centre (Heidelberg)**
- **HOVON** - Hemato-Oncologie voor Volwassenen Nederland
- **IBCSG**—International Breast Cancer Study Group
- **ICR -** Institute of Cancer Research
- **Institut Jules Bordet**
- **ITCC**—Innovative Therapies for Children with Cancer
- **Karolinska University Hsopital**
- **Lawson Health Research Institute (Canada)**
- **MASC** – Melanoma and Skin Cancer Trials

- **Movember**
- **NRG Oncology** – incorporating National Surgical Adjuvant Breast and Bowel Project (NSABP); the Radiation Therapy Oncology Group (RTOG); the Gynecologic Oncology Group (GOG).
- **PrECOG**—Sister Foundation of ECOG
- **PCCTC -** The prostate Cancer Clinical Trials Consortium
- **Royal Marsden NHS Foundation Trust**
- **SIOPE**—European Society for Paediatric Oncology
- **St Anna Kinderkrebsforschung**
- **SWOG**—Southwest Oncology Group
- **TRIO**—Translational Research in Oncology
- **TROG**—Trans-Tasman Radiation Oncology Group
- **UNICANCER (France)**
- **UCL** - University College London
- **University Hospital Freiburg**
- **University Hospital Muenster**
- **University of Birmingham**
- **University of Edinburgh**
- **University of Florence**
- **University of Leeds**
- **University of Liverpool**
- **UPCI –** University of Pittsburgh Cancer Institute
- **Walton Centre NHS Foundation**

Industry collaborations

Since the inception of ICORG, now Cancer Trials Ireland, we have established clinical research partnerships with many global pharmaceutical and biotechnology companies. In 2022 the study portfolio included studies from AbbVie, Astellas, Astra Zeneca, BeiGene, BioProtect, Blueprint, Bristol Myers Squibb, Celgene, Clovis Oncology, Daiichi Sankyo, Glaxo Smith Kline, Immunomedics, Loxo, MSD, Mirati, Morphosys, Nordiv, Novartis, Regeneron, Roche, Sanofi and Syneos Health. The breadth of studies includes early phase I/II clinical trials of novel anticancer agents through to large registration trials for more established treatments.

Specific collaborations during 2022

ANZUP – The Australian New Zealand Urogenital and Prostate Cancer Trials Group
We continued our strong collaboration with ANZUP, which started with two large international phase III trials (ENZAMET and ENZARAD) and continued with DASL, another phase III trial for patients with prostate cancer, which was open to accrual in 2022. For all trials Cancer Trials Ireland is the EU sponsor managing them in Ireland and the UK.

DSCLL – Deutsche Studiengruppe CLL is an important collaboration enacted in 2020 and resulting in the CLL17 study opening in 2021, a phase 3 randomized trial for the treatment of previously untreated chronic Lymphocytic Leukaemia. Accrual to this trial immediately took off and a steady enrolment over the entire year was seen. As a result of the good accrual we were offered now to participate in the CLL18 trial, a phase 3 randomised trial for the treatment of patients with previously untreated Chronic Lymphocytic Leukaemia (CLL) /Small Lymphocytic Lymphoma (SLL).

NRG Oncology
NRG trials are continuously part of the Cancer Trials Ireland portfolio. Currently we have 3 trials in development (for GU, Gynae and Head & Neck cancers) and another 3 trials in follow up (for Breast, GU and Head & Neck cancers)

HOVON – In 2019 we were successful to form a collaboration with the Hemato-Oncologie voor Volwassenen Nederland (HOVON) group and subsequently the HOVON studies 150 and 156, both large phase 3 randomized trials for the treatment of acute myeloid leukemia or myelodysplastic syndrome were opened for accrual in 2021.

ENGOT – Since 2016 we have an active collaboration with the ENGOT, the European Network for Gynaecological Oncological Trial groups, which resulted in the opening of a large number of trials over the years, starting with ENGOT-ov26 and ENGOT-ov45 for ovarian cancer and followed by three trials for cervix cancer ENGOT-cx8, 11 and 12 and ENGOt-en9 (endometrial cancer). In 2022, ENGOT-en15 and ENGOT-ov65 were open to accrual and two more trials are in development.

ETOP - ETOP specialises in European lung cancer research collaboration, and we had already several trials available for Irish patients. A Cancer Trials Ireland investigator has developed an ILT for lung cancer which will be managed in Europe through ETOP and will open in Ireland in the near future.

Staff training (internal)

Training courses conducted by the central office training team along with attendance by central office staff and investigators/ investigational staff at research units.

Type of Training	Number of Sessions	Number of attendees (Central Office Staff)	Number of attendees (Research Unit Staff)
Archiving Training	3	9	0
Budget Training	1	17	0
CAPA Development	1	29	0
Clinical Trial Management System	1	3	0
Clinical Trial Regulation	3	37	0
Data Protection	6	34	0
Disease-specific training: Breast Cancer	1	28	0
Essential Doucment Training	7	15	0
Good Clinical Practice Training	9	33	12
IMP Management	4	8	0
Induction Training: Biometrics	4	27	0
Induction Training: Ethics and Regulatory	5	17	0
Induction Training: Quality and Training	13	26	0
Introduction to Clinical Research and Trials	4	17	0
Introduction to Radiotherapy	1	31	0
Monitoring Visits and Close Out Visits	5	24	0
Patient Registration Training	4	6	0
Pharmacovigilance Training	12	21	0
RECIST 1.1	3	10	0
SOP 8: Site Initiation	3	10	0
Translational Studies - Paper CRF	3	18	0
Trial Master File Training	3	61	0

Staff training (external)

Significant external training courses attended by staff.

Date	Course	Attendees
11-May-22	Surgical Trials Webinar	Associate Project Manage
27-Jun-22	Good Lay Summary Practice	Ethics and Regulatory Manager QA Auditor Ethics and Regulatory Officer
18-Jul-22	Managing and reporting serious breaches of the EU Clinical Trial Regulation	Acting Quality Training Manager
19-Sep-22	Leading Remote and Hybrid Teams	Clinical Operations Lead
20-Oct-22	Data Protection Impact Assessment Workshop	Clinical Project Manager
02 & 03-Nov-22	Data Protection Compliance for Worldwide Clinical Trials	Acting Head of Clinical Operations
12 & 13-Nov-22	Principles of Clinical Quality Assurance Audits	Acting Quality Training Manager
Throughout 2022	HRB Research Integrity Training	Head of Research and Business Development, Associate Project Manager, Clinical Project Manager, Acting Quality Training Manager, QA Auditor, Clinical Data Coordinator, Clinical Data Manager, Database Administrator
Throughout 2022	Oncology CRA Training course	Clinical Research Associate

Cancer trials research unit monitoring

The conduct of a clinical trial should be adequately monitored in order to ensure the reliability and robustness of the results. Monitoring of clinical trials is a requirement of ICH GCP, EU and national regulations. Monitoring activity is carried out on a study by study basis both in the individual cancer research unit and remotely. Each study undergoes a risk analysis, prior to the study being open to patients, which determines the level of monitoring activity and rationale for the chosen monitoring strategy. The risk-based monitoring plan contains detailed information on how the study will be monitored from the time of study initiation to study closure. The COVID pandemic required to develop adaptive strategies to facilitate continued trial conduct and develop resilience for clinical trial conduct in a pandemic reality. It can include the possibility of remote monitoring and close out which, with the support of the hospital, allows for the clinical trial to be monitored without the need to have staff visit the hospital.

The monitoring level can be a combination of on-site or remote and centralised monitoring activities as appropriate to the risk inherent to the type of study and other identified risks. Triggers for decreased or more frequent targeted on-site or remote monitoring visits can be identified in the monitoring plan. The monitoring level can also be determined on a site-by site basis depending on the previous or unknown experience of the investigational site.

Pharmacovigilance

Pharmacovigilance activity	Number
SAEs received and processed by Cancer Trials Ireland * from MOM reviewed studies	83
Collaborative Irish SAEs received and processed (non inhouse studies) SAEs received through Cancer Therapy Evaluation Program's Adverse Expedited Reporting System (CTEP AERS) (includes follow-ups) / MedWatch studies	21
SUSARs Entered onto Eudravigilance Database by Cancer Trials Ireland	6
PhV SOPs updated	0
Annual Development Safety Update Reports (produced in-house) distributed to relevant Ethics Committees and Competent Authorities by Cancer Trials Ireland	9
Annual Development Safety Update Reports (received from another sponsor) distributed to relevant Ethics Committees and Competent Authorities by Cancer Trials Ireland	7
6 Monthly SUSAR line listings produced	23
Safety and clinical database reconciliations	30

Audits

Number of days spent in 2022 preparing for and conducting audits and follow-up activity as well as active participation in external sponsor and third party audits at our central office and at cancer trials research units around the country.

Audit Type	Preparation (days)	Audit (days)	Follow up (days)
Cancer Trials Ireland Internal Audits	16	10	22
Cancer Trials Ireland Audit of Research Units	0	0	12
Cancer Trials Ireland Audit of Third parties/vendors	11	2	5.5
Audit strategy/planning and audit/inspection readiness	4.75	-	-
Total	**31.75**	**12**	**39.5**

Participation in conferences & meetings

Date	Meeting
26/01/2022	Launch of IHI
04/02/2022	ILCA Attendance
08/02/2022	Health Summit
16/02/2022	BNOS webinar
27/04/2022	AICRI workshop
28-29/04/2022	John Fitzpatrick Irish Genitourinary Cancer Conference 2022
28-29/04/2022	ENGOT Copenhagen
04/05/2022	CLL Ireland conference
11-12/05/2022	EUCON22: Virtual European QA Congress 2022
12/05/2022	NCTO ICTD conference
17/05/2022	ICTD conference on accrual
	GCIG translational meeting (prep for Chicago)
20/05/2022	Cancer Retreat
20/05/2022	Irish Melanoma Forum
24/05/2022	> GLSP Workshop: update Tara and Sheila & e-mail to Eibh
26/05/2022	Functional Cancer Genomics & Precision Oncology Workshop
02/06/2022	GCIG Chicago
03-06/06/22	ASCO Chicago
09-12/06/2022	EHA
22/06/2022	BIG General Assembly - 22 June 2022 (Virtual)
04/07/2022	ISMO - ASCO updates
08/07/2022	> UCC Cancer Summer Series.
11-13/07/2022	ISMO - post ASCO review sessions I'd say this was just a listen back
02/09/2022	National Haematology Summit
09/09/2022	BCNI summit - Galway
09-12/09/2022	ESMO
23-24/09/2022	All Ireland Lung Cancer Conference
28/09/2022	AICRI showcase
28/09/2022	International Symposium on Translational Research in Oncology (CCRT: Metastatic Breast cancer (Sara Hurvitz))
29-30/09/2022	International Symposium on Translational Research in Oncology
05/10/2022	RQA Virtual Open Day: 3 talks - Focusing on Prevention, Inspection Readiness, GMP/GCP
06-07/10/2022	ENGOT
14/10/2022	All Ireland Colorectal Cancer Conference
14/10/2022	EORTC GU DSSG
	AICCC
19/10/2022	EORTC breast webinar
22/10/2022 & 25/10/2022	ASTRO
27/10/2022	NREC webinar
01/11/2022	Brain Tumour Ireland meeting in RCSI
09-11/11/2022	RQA Annual Conference: Re:United Brighton
17-18/11/2022	The Gathering around Cancer
24/11/2022	NCTO QWG HPRA compliance meeting attendance
30/11/2022	HRB national conference
01/12/2022	Irish Sarcoma Group Scientific Meeting
06/12/2022	HBR webinar: EU funding in cancer research

Communications

Increasing awareness of Cancer Trials Ireland

A number of activities are undertaken during the year to increase the awareness of cancer trials and showcase the work that is being done across the country. These opportunities will continue to be pursued during the coming years. They include the following:

- **International Clinical Trials Day**: This is the organisation's annual set piece publicity event which results in a boost to the organisation's profile, the work of its members and contribution of patients. In 2022, we hosted Ireland's the second Cancer Retreat, which was a hybrid event attended by 250+ members of the Irish clinical oncology research community virtually & in person. This was supported by significant digital and media communications leveraging patient stories, where possible on Investigator-Led Trials, to maximise the reach of our message to "Just Ask".

- **Mainstream media relations**: We are placing stories in local and national media on the opening of trials and announcing trial results. Features are also placed in national newspapers such as The Irish Independent, Irish Times, Irish Examiner, Sunday Business Postand Irish Tabloids and magazines.

- **Specialist media relations**: Details of trials are featured regularly in specialist medical press such as the Medical Independent, Cancer Professional and UPDATE Oncology and Haematology Journal.

- **Online**: In 2022 we continued to augment out upgraded website with video content created for and around the Cancer Retreat. Regular updates on topical news and cancer trials listing are provided on our website (www.cancertrials.ie) and regular posting on our Twitter and LinkedIn accounts, with the numbers of followers continuing to grow steadily. Our Vimeo account hosts our videos.

- **DSSG Digest**: The DSSG Digest newsletter lists the latest news and up to date listing of open cancer trials. It is widely distributed within the community (including the media) both electronically and in hard copy.

- **Annual Review**: The publication of the organisation's Annual Review is another opportunity used to profile the organisation's successes and progress.

- **Conferences:** Attendances at conferences are used regularly to raise the profile of the organisation's work

- **Quarterly accruals published:** We established a process for publishing the accruals figures for each quarter, broken down by study type and disease area. members on study news and updates.

Implementing public and patient involvement (PPI)

- In October 2022, Cancer Trials Ireland appointed Sarah McLoughlin as Public & Patient Involvement Co-ordinator.

- Also in October 2022, the PCC and PPI Co-ordinator, and the Head of Communications, took part in a strategy workshop to clarify Terms of Reference and strategic planning for the coming year.

- In 2022, the PCC appointed a new vice-chair (Peter MacNamara)

- Siobhan Gaynor (PCC member) was a panellist at the Cancer Retreat

- The CTI Autumn DSSG stakeholder meeting focused on PPI, and featured the newly appointed PPI-Co-ordinator for Cancer Trials Ireland, Sarah McLoughlin

- Several of the Disease Specific Sub-Groups (DSSGs) have patient consultants in attendance at closed meetings.

- The Patient Consultant's Committee (PCC) was set up as a sub-group of the Board in 2018. The Chair of the PCC now sits on the Board of Cancer Trials Ireland and a new Chair was appointed in 2020.

Publications

This metric records the publications in peer-reviewed journals and abstracts accepted at top level international meetings based on the findings of trials the Members of Cancer Trials are, or have been, involved in.

Area	Peer Reviewed Journal Articles 2022	Abstracts: Poster/Oral Presentations 2022
Basket	2	0
Breast	7	2
CNS	0	1
Gastrointestinal	1	3
Genitourinary	8	1
Gynaecological	8	5
Head and Neck	0	0
Lung	3	0
Lymphoma and Haematological	2	0
Melanoma	0	0
Other	1	4
Total	**32**	**16**

*Compiled from approval for/notification of abstracts received by Cancer Trials Ireland from Investigators. Potentially additional abstracts have been presented.

Peer reviewed journal publications

Basket

Cancer Trials Ireland Study Number: Short Name. 15-42: LOXO 101 study
Waguespack, S. G., A. Drilon, J. J. Lin, M. S. Brose, R. McDermott, M. Almubarak, J. Bauman, M. Casanova, A. Krishnamurthy, S. Kummar, S. Leyvraz, D. Y. Oh, K. Park, D. Sohal, E. Sherman, R. Norenberg, J. D. Silvertown, N. Brega, D. S. Hong & M. E. Cabanillas (2022). **"Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma."** Eur J Endocrinol, 186(6): 631-643. PMID: 35333737

Cancer Trials Ireland Study Number: Short Name. 15-42: LOXO 101 study (Online ahead of print)
Le, X., C. Baik, J. Bauman, J. Gilbert, M. S. Brose, J. E. Grilley-Olson, T. Patil, R. McDermott, L. Raez, J. M. Johnson, L. Shen, M. Tahara, A. L. Ho, R. Norenberg, L. Dima, N. Brega, A. Drilon, D. S. Hong (2022).**"Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers"** **Oncologist.**, oyac080. **PMID: 35536733**

Breast

Cancer Trials Ireland Study Number: short name. 15-16: FLIPPER
Albanell, J., M. T. Martínez, M. Ramos, M. O'Connor, L. de la Cruz-Merino, A. Santaballa, N. Martínez- Jañez, F. Moreno, I. Fernández, J. Alarcón, J. A. Virizuela, J. de la Haba-Rodríguez, P. Sánchez-Rovira, L. González-Cortijo, M. Margelí, A. Sánchez-Muñoz, A. Antón, M. Casas, S. Bezares and F. Rojo (2022). **"Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2 –advanced breast cancer: GEICAM/2014–12 (FLIPPER)."** Eur J Cancer, 161: 26-37. PMID: 34902765

CTRIAL-IE 10-06: TROG DCIS
Chua, B. H., E. K. Link, I. H Kunkler, T. J. Whelan, A. H. Westenberg, G. Gruber, G. Bryant, V. Ahern, K. Purohit, P. H. Graham, M. Akra, O. McArdle, P. Brien, J. A. Harvey, C. Kirkove, J. H. Maduro, I. D. Campbell, G. P. Delaney, J. D. Martin, T. T. Vu, T. M. Muanza, A. Neal, I. A. Olivotto, BIG 3–07/TROG 07.01 trial investigators (2022). "**Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast**

(BIG 3-07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study." Lancet 400 (10350):431-440. PMID: 35934006

CTRIAL-IE 10-11: Circulating miRNAs

Davey, M. G., M. C. Casey, A. McGuire, R. M. Waldron, M. Paganga, E. Holian, J. Newell, H. M. Heneghan, A. M. McDermott, M. M. Keane, A. J. Lowery, N. Miller, M. J. Kerin (2022) **"Evaluating the Role of Circulating MicroRNAs to Aid Therapeutic Decision Making for Neoadjuvant Chemotherapy in Breast Cancer: A Prospective, Multicenter Clinical Trial."** Ann Surg 276(5):905-912. PMID: 35876391

CTRIAL-IE 10-11: Circulating miRNAs
Davey, M. G., A. McGuire, M. C. Casey, R. M. Waldron, M. Paganga, E. Holian, J. Newell, H. M. Heneghan, A. M. McDermott, M. M. Keane, A. J. Lowery, N. Miller, M. J. Kerin (2022) **"Evaluating the Role of Circulating MicroRNAs in Predicting Long-Term Survival Outcomes in Breast Cancer: A Prospective, Multicenter Clinical Trial"** J Am Coll Surg. 236(2):317-327. PMID: 36648259

CTRIAL-IE 14-11: Penelope-B
Galactionova, K., S. Loibl, P. Salari, F. Marmé, M. Martin, M. Untch, H. R. Bonnefoi, S. Kim, H. D. Bear, N. McCarthy, K. A. Gelmon, J. A. García-Sáenz, C. M. Kelly, T. Reimer, M. Toi, H.S Rugo, M. Gnant, A. Makris, N. Burchardi, M. Schwenkglenks (2022) **"Cost-effectiveness of palbociclib in early breast cancer patients with a high risk of relapse: Results from the PENELOPE-B trial."** Front Oncol 12:886831. PMID: 36132153

CTRIAL-IE 12-43: PALOMA-2
Rugo, H. S, S. Im, A. A. Joy, Y. Shparyk, J. M. Walshe, B. Sleckman, S. Loi, K. P. Theall, S. Kim, X. Huang, E. Bananis, R. Mahtani, R. S. Finn, V. Diéras (2022**) "Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: Post hoc analyses from PALOMA-2 and PALOMA-3"** Breast 66:324-331. PMID: 36463643

CTRIAL-IE 15-49: NeoTRIP

Gianni, L., C. S. Huang, D. Egle, B. Bermejo, C. Zamagni, M. Thill, A. Anton, S. Zambelli, G. Bianchini, S. Russo, E. M. Ciruelos, R. Greil, V. Semiglazov, M. Colleoni, C. Kelly, G. Mariani, L. Del Mastro, I. Maffeis, P. Valagussa, G. Viale (2022) **"Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study"** Ann Oncol 33(5):534-543. PMID: 35182721

Gastrointestinal

CTRIAL-IE 14-19: BMS CA209-142/ CheckMate 142
André, T., S. Lonardi, K Y M Wong, H-J Lenz, F. Gelsomino, M. Aglietta, M. A. Morse, E. Van Cutsem, R. McDermott, A. Hill, M. B. Sawyer, A. Hendlisz, B. Neyns, S. Abdullaev, A. Memaj, M. Lei, M. Dixon, S. Kopetz , M. J. Overman (2022) **"Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142."** Ann Oncol 33(10):1052-1060. PMID: 35764271

Genitourinary

Cancer Trials Ireland Study Number: Short Name. 14-06: ENZAMET
Stockler, M. R., A. J. Martin, I. D. Davis, H. M. Dhillon, S. D. Begbie, K. N. Chi, S. Chowdhury, X. Coskinas, M. Frydenberg, W. E. Hague, L. G. Horvath, A. M. Joshua, N. J. Lawrence, G. M. Marx, J. McCaffrey, R. McDermott, M. McJannett, S. A. North, F. Parnis, W. R. Parulekar, D. W. Pook, M. N. Reaume, S. Sandhu, A. Tan, T. H. Tan, A. Thomson, F. Vera-Badillo, S. G. Williams, D. G. Winter, S. Yip, A. Y. Zhang, R. R. Zielinski, C. J. Sweeney & ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Group (ANZUP) (2022). **"Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP."** J Clin Oncol, 40(8): 837-846. PMID: 34928708

CTRIAL-IE 13-09: PEACE-1
Fizazi, K., S. Foulon , J. Carles, G. Roubaud , R. McDermott , A. Fléchon , B. Tombal , S. Supiot , D. Berthold , P. Ronchin, G. Kacso, G. Gravis, F. Calabro, J.F Berdah, A. Hasbini, M. Silva, A.T Vuillemin, I. Latorzeff, L. Mourey, B.

Laguerre, S.A Lacourtoisie, E. Martin, C. El. Kouri, A. Escande, A. Rosello, N. Magne, F. Schlurmann, F. Priou, M. C. Fouche, S.V Freixa, M. Jamaluddin, I. Rieger, A. Bossi, PEACE-1 investigators (2022). "**Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design."** **Lancet** 399(10336):1695-1707 PMID: 35405085

CTRIAL-IE (ICORG 97-01) Prostate

Kishan, A. U., Y. Sun, H. Hartman, T. M. Pisansky, M. Bolla, A. Neven, A. Steigler, J. W. Denham, F. Y. Feng, A. Zapatero, J. G. Armstrong, A. Nabid, N. Carrier, L. Souhami, M. T. Dunne, J. A. Efstathiou, H. M. Sandler, A. Guerrero, D. Joseph, P. Maingon, T. M. Reijke, X. Maldonado, T. Martin Ma, T. Romero, X. Wang, M. B Rettig, R. E Reiter, N. G Zaorsky, M. L Steinberg, N. G Nickols, A. Y Jia, J. A Garcia, D. E Spratt, MARCAP Consortium group (2022). "**Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis."** **Lancet Oncol** 23(2):304-316. PMID: 35051385

ICORG 97-01 Prostate (a meta analysis)

Ma, T. M, F. Chu, H. Sandler, F. Y. Feng, J. A. Efstathiou, C. U. Jones, M. Roach, S. A. Rosenthal, T. Pisansky, J. M. Michalski, M. Bolla, T. M. Reijke, P. Maingon, A. Neven, J. Denham, A. Steigler, D. Joseph, A. Nabid, L. Souhami, N. Carrier, L. Incrocci, W. Heemsbergen, F. J. Pos, M. R. Sydes, D. P. Dearnaley, A. C. Tree, I. Syndikus, E. Hall, C. Cruickshank, S. Malone, S. Roy, Y. Sun, N. G. Zaorsky, N. G. Nickols, R. E. Reiter, M. B. Rettig, M. L. Steinberg, V. K. Reddy, M. Xiang, T. Romero, D. E. Spratt, A. U. Kishan (2022). **"Local Failure Events in Prostate Cancer Treated with Radiotherapy: A Pooled Analysis of 18 Randomized Trials from the Meta-analysis of Randomized Trials in Cancer of the Prostate Consortium (LEVIATHAN)."** **Eur Urol** 82 (5):487-498. PMID: 35934601

CTRIAL-IE 15-46: PACE-B

Tree C. A., P. Ostler, H. van der Voet, W. Chu, A. Loblaw, D. Ford, S. Tolan, S. Jain, A. Martin, J. Staffurth, J. Armstrong, P. Camilleri, K. Kancherla, J. Frew, A. Chan, I. S. Dayes, A. Duffton, D. H. Brand, D. Henderson, K. Morrison, S. Brown, J. Pugh, S. Burnett, M. Mahmud, V. Hinder, O. Naismith, E. Hall, As. N. Van, PACE Trial Investigators (2022) **"Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial."** **Lancet Oncol** 1308-1320. PMID: 36113498

CTRIAL-IE (ICORG) 07-11: SCC Retreat

Wallace, N. D., M. T. Dunne, O. McArdle, C. Small, I. Parker, A. M. Shannon, A. Clayton-Lea, M. Parker, C. D. Collins, J. G. Armstrong, C. Gillham, J. Coffey, D. Fitzpatrick, O. Salib, M. Moriarty, M. R. Stevenson, A. Alvarez-Iglesias, M. McCague, P. G. Thirion **"Efficacy and toxicity of primary re-irradiation for malignant spinal cord compression based on radiobiological modelling: a phase II clinical trial"** (2023) **Br J Cancer** 128(4):576-585. PMID: 36482188

CTRIAL-IE 17-30: IRONMAN

Mucci, L. A, J. Vinson, T. Gold, T. Gerke, J. Filipenko, R. M. Green, S. G. Anderson, S. Badal, A. Bjartell, K. N. Chi, I. D. Davis, D. Enting, A. P. Fay, J. Lazarus, J. Mateo, R. McDermott, F. T. Odedina, D. Olmos, A. Omlin, A. A. Popoola, C. Ragin, R. Roberts, K. M. Russnes, C. Waihenya, K. H. Stopsack, T. Hyslop, P. Villanti, P. W. Kantoff, D. J. George, IRONMAN Global Team (2022**) "IRONMAN: A Novel International Registry of Men With Advanced Prostate Cancer"** JCO Glob Oncol e2200154. PMID: 36332173

CTRIAL-IE (ICORG) 12-22: BMS CA209-025

Schmidinger, M., R. J. Motzer, F. Rolland, M. Staehler, M. Rink, M. Retz, T. Csoszi, J. A. McCaffrey, U. Giorgi, C. Caserta, I. Duran, F. Benzaghou, D. O. Clary, L. Albiges, T. K. Choueiri, N. M. Tannir (2022) **"Analysis by region of outcomes for patients with advanced renal cell carcinoma treated with cabozantinib or everolimus: a sub-analysis of the METEOR study"** **Acta Oncol.** 61(1):52-57. **PMID: 34736367**

Gynaecological

CTRIAL-IE 16-04: PRIMA

O'Cearbhaill, R. E., Jose-Alejandro Pérez-Fidalgo, B. J Monk, I. Tusquets, C. McCormick, J. Fuentes, R. G. Moore, C. Vulsteke, M. S. Shahin, F. Forget, W. H. Bradley, S. Hietanen, D. M. O'Malley, A. Dørum, B. M. Slomovitz, K. Baumann, F. Selle , P. M. Calvert, G. Artioli, T. Levy, A. Kumar, I. A. Malinowska, Y. Li, D. Gupta,

Antonio G. M (2022) "**Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study."** **Gynecol Oncol** 166(1):36-43. PMID: 35550709

Recommendation Paper - not study related

Vergote, I., A. Gonzalez-Martin, D. Lorusso, C. Gourley, M. Raza Mirza, J. Kurtz, A. Okamoto, K. Moore, F. Kridelka, I. McNeish, A. Reuss, B. Votan, A. du Bois, S. Mahner, I. Ray-Coquard, E. C. Kohn, J. S. Berek, D. S. P Tan, N. Colombo, R. Zang, N. Concin, D. O'Donnell, A. Rauh-Hain, C. Simon Herrington, C. Marth, A. Poveda, K. Fujiwara, G. C. E Stuart, A. M. Oza, Michael A Bookman, participants of the 6th Gynecologic Cancer InterGroup (GCIG) Ovarian Cancer Consensus Conference on Clinical Research (2022) "**Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup."** **Lancet Oncol** e374-e384. PMID: 35901833

CTRIAL-IE 18-26: ATHENA

Monk, B. J., C. Parkinson, M. Cheol Lim, D. M. O'Malley, A. Oaknin, M. K. Wilson, R. L. Coleman, D. Lorusso, P. Bessette, S. Ghamande, A. Christopoulou, D. Provencher, E. Prendergast, F. Demirkiran, O. Mikheeva, O. Yeku, A. Chudecka-Glaz, M. Schenker, R. D. Littell, T. Safra, H. Chou, M.A. Morgan, V. Drochýtek, J. N. Barlin, T. Van Gorp, F. Ueland, G. Lindahl, C. Anderson, D. C. Collins, K. Moore, F. Marme, S. N. Westin, I. A. McNeish, D. Shih, K. K. Lin, S. Goble, S. Hume, K. Fujiwara, R. S. Kristeleit (2022) **"A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45)."** **J Clin Oncol** JCO.22.01003. PMID: 35658487

CTRIAL-IE 11-21: ICON 8B

Clamp, A. R., E. C. James, I. A. McNeish, A. Dean, J. Kim, D. M. O'Donnell, D. Gallardo-Rincon, S. Blagden, J. Brenton, T. J. Perren, S. Sundar, R. Lord, G. Dark, M. Hall, S. Banerjee, R. M. Glasspool, C. Louise Hanna, S. Williams, K. M. Scatchard, H. Nam, S. Essapen, C. Parkinson, L. McAvan, A. Marie Swart, B. Popoola, F. Schiavone, J. Badrock, F. Fananapazir, A. D. Cook, M. Parmar, R. Kaplan, J. A. Ledermann (2022) **"Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial."** **Lancet Oncol** 23 (7):919-930. PMID: 35690073

Recommendation Paper - not study related

Mac Eochagain, C., R. Power, I. Parker & D. Brennan (2022). **"HPV vaccination among seropositive, DNA negative cohorts: a systematic review & meta-analysis."** J Gynecol Oncol, 33(3): e24. PMID: 35128855

Recommendation Paper - not study related

Woopen, H., J. Sehouli, A. Davis, Y. C. Lee, P. A. Cohen, A. Ferrero, N. Gleeson, A. Jhingran, Y. Kajimoto, J. Mayadev, M. P. Barretina-Ginesta, S. Sundar, N. Suzuki, E. van Dorst & F. Joly (2022)**." Erratum to "GCIG-Consensus guideline for long-term survivorship in gynecologic cancer: A position paper from the Gynecologic Cancer InterGroup (GCIG) symptom benefit committee" [Cancer Treatm. Rev. 107 (2022) 102396]."** **Cancer Treat Rev** 109:102431. PMID: 35803179

CTRIAL-IE 10-12: ANZGOG-0701 Symptom Benefit Study

Lee, Y. C., M. T. King, R. L. O'Connell, A. Lanceley, F. Joly, F. Hilpert, A. Davis, F. T. Roncolato, A. Okamoto, J. Bryce, P. Donnellan, A. M. Oza, E. Avall-Lundqvist, J. S. Berek, J. A. Ledermann, D. Berton, J. Sehouli, A. Feeney, M. Kaminsky, K. Diamante, M. R. Stockler, M. L. Friedlander, GCIG Symptom Benefit Group (2022) **"Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecological Cancer Inter-Group-Symptom Benefit Study."** **Int J Gynecol Cancer** 32(6):761-768. PMID: 35086926

Recommendation Paper - not study related

Woopen, H., J. Sehouli, A. Davis, Y. C. Lee, P. A. Cohen, A. Ferrero, N. Gleeson, A. Jhingran, Y. Kajimoto, J. Mayadev, M. P. Barretina-Ginesta, S. Sundar, N. Suzuki, E. van Dorst, F. Joly **(2022)"GCIG-Consensus guideline for Long-term survivorship in gynecologic Cancer: A position paper from the gynecologic cancer Intergroup (GCIG) symptom benefit committee"** **Cancer Treat Rev.** 107:102396. **PMID: 35525106**

Lung

CTRIAL-IE 16-59: ETOP ALERT

Felip, E., E. F. Smit, M. A. Molina-Vila, U. Dafni, B. Massuti, T. Berghmans, F.de Marinis, F. Passiglia, A. C.

Dingemans, M. Cobo, S. Viteri, C. Britschgi, S. Cuffe, M. Provencio, S. Merkelbach-Bruse, C. Andriakopoulou, R. Kammler, B. Ruepp, H. Roschitzki-Voser, S. Peters, J. Wolf, R. Stahel, ETOP 12-17 ALERT-lung Collaborators (2022) **"Alectinib for the treatment of pretreated RET-rearranged advanced NSCLC: Results of the ETOP ALERT-lung trial."** **Lung Cancer** 172:94-99. PMID: 36030612

CTRIAL-IE 16-61: ETOP BOOSTER

Dafni, U., R. A. Soo, S. Peters, Z. Tsourti, P. Zygoura, K. Vervita, J-Y Han, J. De Castro, L. Coate, M. Früh, S. M S. Hashemi, E. Nadal, E. Carcereny, M. A. Sala, R. Bernabé, M. Provencio, S. Cuffe, H. Roschitzki-Voser, B. Ruepp, R. Rosell, R. A. Stahel (2022) **"Impact of smoking status on the relative efficacy of the EGFR TKI/ angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysis."** **ESMO Open** 7(3):100507. PMID: 35696746

Cancer Trials Ireland Study Number: Short Name. 20-02: TERAVOLT Registry

Whisenant, J. G., J. Baena, A. Cortellini, L. C. Huang, G. L. Russo, L. Porcu, S. K. Wong, C. M. Bestvina, M. D. Hellman, E. Roca, H. Rizvi, I. Monnet, A. Boudjemaa, J. Rogado, G. Pasello, N. B. Leighl, O. Arrieta, A. Aujayeb, U. Batra, A. Y. Azzam, M. Unk, M. A. Azab, A. N. Zhumagaliyeva, C. Gomez-Martin, J. B. Blaquier, E. Geraedts, G. Mountzios, G. Serrano-Montero, N. Reinmuth, L. Coate, M. Marmarelis, C. J. Presely, F. R. Hirsch, P. Garrido, H. Khan, A. Baggi, C. Mascaux, B. Halmos, G. L. Ceresoli, M. J. Fidler, V. Scotti, A. C. Métivier, L. Falchero, E. Felip, C. Genova. J. Mazieres, U. Tapan, J. Brahmer, E. Bria, S. Puri, S. Popat, K. L. Reckamp, F. Morgillo, E. Nadal, F. Mazzoni, F. Agustoni, J. Bar, F. Grosso, V. Avrillon, J. D. Patel, F. Gomes, E. Ibrahim, A. Trama, A. C. Bettini, F. Barlesi, A. M. Dingemans, H. Wakelee, S. Peters, L. Horn, M. C. Garassino, V. Torri & TERAVOLT study group (2022). **"A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry."** J Thorac Oncol, 17 (5): 661-674. PMID: 35121086

Lymph & Haem

Cancer Trials Ireland Study Number: Short Name. 13-17: RsqVD

O'Gorman, P., J. P. Laubach, M. E. O'Dwyer, J. Krawczyk, A. J. Yee, O. Gilligan, M. R. Cahill, J. Rosenblatt, J. Quinn, P. T. Murphy, H. DiPietro, M. R. Perera, G. M. Crotty, K. Cummings, P. J. Hayden, P. Browne, A. Savell, H. M. O'Leary, D. O'Keeffe, K. Masone, B. J. Hennessy, T. G. Garcia, K. Scott, K. Saeed, G. Bianchi, P. Dowling, C. Tierney & P. G. Richardson (2022). **"Phase 2 studies of lenalidomide, subcutaneous bortezomib, and dexamethasone as induction therapy in patients with newly diagnosed multiple myeloma."** Am J Hematol, 97(5): 562-573. PMID: 35132679

CTRIAL-IE 16-02: CyBorD-DARA

Swan, D., R. Henderson, C. McEllistrim, S. D. Naicker, J. Quinn, M. R. Cahill, V. Mykytiv, E. Lenihan, E. Mulvaney, M. Nolan, I. Parker, A. Natoni, K. Lynch, A. E. Ryan, E. Szegezdi, J. Krawczyk, P. Murphy, M. O'Dwyer (2022) **"CyBorD-DARA in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Results from the 16-BCNI-001/CTRIAL-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment."** **Clin Lymphoma Myeloma Leuk** 22(11):847-852. PMID: 35985959

Other

O'Reilly, S., V. Murphy, E. Mulroe, L. Tucker, F. Carragher, J. Marron, A. Shannon, K. Rogan, R. M. Connolly, B. T. Hennessy, R. S. McDermott 1 **(2022) "The SARS-CoV-2 Pandemic and Cancer Trials Ireland: Impact, Resolution and Legacy"** **Cancers (Basel)** 14(9):2247. PMID: 35565375

Abstracts: Oral and Poster Presentations

Breast

CTRIAL-IE 12-30: TAILORx Tissuebank Study

Lucas, M., Z. Kinsella, C. A. Gonzalez, C. Hurley, A. Blümel, J. Fay, A. O'Grady, V. Murphy, C. Arif Jahangir, C. Burke, A. Rahman, J. Crown, C. Margaret Kelly, W. M. Gallagher, D. O'Connor (2022) **"CD45-positive tumor infiltrating lymphocytes in early-stage hormone-positive, HER2-negative (ER+/HER2-) breast cancer: Correlation with proliferation and prognostic signature scores."** Publication - **ASCO-2022-Tumour infiltrating lymphocytes** (suppl 16; abstr e12555) 10.1200/JCO.2022.40.16_suppl.e12555

CTRIAL-IE 12-43: TRIO 022/ Paloma-2

Finn, R. S., H. S. Rugo, V. C Dieras, N. Harbeck, S. Im, K. A. Gelmon, J. M. Walshe, M. Martin, M. Chavez Mac Gregor, E. Bananis, E. R. Gauthier, D. Ray Lu, S.Kim, D. J. Slamon2022) **"Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/**

HER2− ABC): Analyses from PALOMA-2." Oral Abstract - **ASCO-2022-ER+/HER2− ABC** (suppl 17; abstr LBA1003) 10.1200/JCO.2022.40.17_suppl.LBA1003

CNS

CTRIAL-IE 15-42: LOXO 101 and CTRIAL-IE 18-36 LOXO TRK 15003
Drilon, A. E., D. S. Hong, C. Martinus van Tilburg, F. Doz, D. S. W. Tan, S. Kummar, J. Jiyeong Lin, R. S. McDermott, C. Michel Zwaan, R. Norenberg, M. Mardoche Fellous, N. Brega, R. Xu, T. Willis Laetsch, L. Shen (2022) **"Long-term efficacy and safety of larotrectinib in a pooled analysis of patients with tropomyosin receptor kinase (TRK) fusion cancer."** Poster - **ASCO-2022-tyrosine receptor kinase** (suppl 16; abstr 3100) 10.1200/JCO.2022.40.16_suppl.3100

Gastrointestinal

CTRIAL-IE 14-20: STRATEGIC-1
Chibaudel, B., L. Dourthe, T. Andre, J. Henriques, V. Bourgeois, P. Etienne, J. Desrame, E. Carola, O. Dupuis, N. Baba-Hamed, D. Auby, C. Louvet, E. Maillard, O. Romano, C. Tournigand, M. Garcia-Larnicol, E. Shacham Shmueli, B. Healey Bird, F. Ghiringhelli, A.De Gramont (2022) **"STRATEGIC-1: Multi-line therapy trial in unresectable wild -type KRAS/NRAS/BRAF metastatic colorectal cancer—A GERCOR-PRODIGE randomized open-label phase III study."** Oral Abstract – **ASCO 2022 - GERCOR STRATEGIC-1** (suppl 16; abstr 3504) 10.1200/JCO.2022.40.16_suppl.3504

CTRIAL-IE 12-38: TRI-LARC
Geary, R., C. Gillham, G. McVey, J. Armstrong, M. Cunningham, G. Rangaswamy, D. Sharma, N. Wallace, C. Skourou, M. Dunne, M. Mahon, S. Bradshaw, L. Osullivan, J. Marron, I. Parker, A. Shannon, R. Mcdermott, S. Toomey, B. Hennessy, B. O'Neill (2022) **"Quality of life analysis of a phase II randomised controlled trial comparing 3D-Conformal Radiotherapy (3D-CRT) and Intensity Modulated Radiotherapy (IMRT) in locally advanced rectal cancer (TRI-LARC)."** In print.

CTRIAL-IE 14-19: BMS CA209-142/ CheckMate 142
Overman, M. J., H. Lenz, T. Andre, M. Aglietta, M. Ka Wong, G. Luppi, E. Van Cutsem, R. S. McDermott, A. Hendlisz, D. Backlund Cardin, M. Morse, B. Neyns, A. Graham Hill, M. Luisa Limon, P. Garcia-Alfonso, A. Krishnamurthy, F. Chen, S. Abdullaev, S. Soleymani, S. Lonardi (2022) **"Nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Five-year follow-up from CheckMate 142."** Poster Discussion - **ASCO-2022-metastatic colorectal cancer** (suppl 16; abstr 3510) 10.1200/JCO.2022.40.16_suppl.3510

Genitourinary

CTRIAL-IE 19-32: DASL HiCAP
Niazi, T., S. M. McBride, S. Williams, I. D. Davis, M. R. Stockler, A .James Martin, K. Bracken, F. Roncolato, L. Horvath, S. Sengupta, J. Martin, T. Lim, S. Hughes, R. S. McDermott, J. W. F. Catto, P. J. Kelly, W. R. Parulekar, S. Carlyle Morgan, R. A. Rendon, C. Sweeney (2022) **"DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)—A randomized phase 3, double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation."** Poster - **ASCO -2022 - DASL-HiCaP** (suppl 16; abstr TPS5103) 10.1200/JCO.2022.40.16_suppl.TPS5103

Gynaecological

CTRIAL-IE 18-35: ENGOT cx8/ GCT 1015-05
Vergote, I., M. R. Mirza, J. Sehouli, D. Lorusso, F. Köse, D. Cibula, A. M. Westermann, D. C. Collins, S. N. Banerjee, A. Oaknin, I. Soumaoro, S. Jain, B. J. Monk (2022) **"Trial in progress update on ENGOT-cx8/GOG-3024/ innovaTV 205: Addition of a new cohort with first-line (1L) tisotumab vedotin (TV) + pembrolizumab (pembro) + carboplatin (carbo) ± bevacizumab (bev) in recurrent/metastatic cervical cancer (r/mCC)."** Poster - **ASCO-2022-recurrent/metastatic cervical cancer** (suppl 16; abstr TPS5603) 10.1200/JCO.2022.40.16_suppl.TPS5603

CTRIAL-IE 18-35: ENGOT cx8/ GCT 1015-05
Lorusso, D., I. Vergote, R. E. O'Cearbhaill, A. M. Westermann, S. N. Banerjee, E. V. Nieuwenhuysen, D. A. Iglesias, D. C. Collins, D. Cibula, K. Madsen, K. S. Tewari, S. Pignata, J. F. Baurain, I. A. Boere, H. denys, C. M. Andreassen, I. Soumaoro, S. Jain, C. N. Gennigens, B. J. Monk (2022) **"Tisotumab vedotin (TV) + pembrolizumab (pembro) in first-line (1L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT Cx8/GOG 3024/innovaTV 205."** Oral Abstract - **ASCO-2022-ENGOT Cx8/GOG 3024/innovaTV 205** (suppl 16; abstr 5507) 10.1200/JCO.2022.40.16_suppl.5507

CTRIAL-IE 18-26: ATHENA – GOG-3020/ ENGOT ov45

Monk, B. J., C. Parkinson, M. C. Lim, D. M. O'Malley, A. Oaknin, M. K. Wilson, R. L. Coleman, D. Lorusso, A. M. Oza, S. A. Ghamande, A. Christopoulou, E. Prendergast, F. Demirkiran, R. D. Littell, Anita M. Chudecka-Glaz, Mark Aloysuis Morgan, Sandra M. Goble, Stephanie Hume, Keiichi Fujiwara, Rebecca Kristeleit (2022) **"ATHENA–MONO (GOG-3020/ENGOT-ov45): A randomized, double-blind, phase 3 trial evaluating rucaparib monotherapy versus placebo as maintenance treatment following response to first-line platinum-based chemotherapy in ovarian cancer."** Oral Abstract - **ASCO-2022-ATHENA–MONO (GOG-3020/ENGOT-ov45)** (suppl 17; abstr LBA5500) 10.1200/JCO.2022.40.17_suppl.LBA5500

CTRIAL-IE 22-03: ENGOT ov65

Colombo, N., R. L. Coleman, X. Wu, F. Köse, R. Michael Wenham, A. Sebastianelli, K. Hasegawa, E. Zsiros, T. De La Motte Rouge, M. Bidziński, I. A. McNeish, J. Sehouli, J. Korach, P. R. Debruyne, J. Kim, A. C. de Melo, X. Peng, A. M. Bogusz, K. Sayuri Yamada, B. J. Monk (2022) **"ENGOT-ov65/KEYNOTE-B96: Phase 3, randomized, double-blind study of pembrolizumab versus placebo plus paclitaxel with optional bevacizumab for platinum-resistant recurrent ovarian cancer."** Poster - **ASCO-2022-ENGOT-ov65/KEYN\OTE-B96** (suppl 16; abstr TPS5617) 10.1200/JCO.2022.40.16_suppl.TPS5617

CTRIAL-IE 22-02: ENGOT en15

Slomovitz, B. M., D. Cibula, T. Simsek, M. R. Mirza, B. Maćkowiak-Matejczk, E. Hudson, I. Romero, N. Colombo, J. Korach, R. Yin, L. Gilbert, K. Hasegawa, A. Tyulyandina, S. E. Baron-Hay, L. Willmott, F. J. Backes, R. J. Orlowski, X. Zhou, V. Khemka, S. Pignata (2022) **"KEYNOTE-C93/GOG-3064/ENGOT-en15: A phase 3, randomized, open-label study of first-line pembrolizumab versus platinum-doublet chemotherapy in mismatch repair deficient advanced or recurrent endometrial carcinoma."** Poster - **ASCO-2022-KEYNOTE-C93/GOG-3064/ENGOT-en15** (suppl 16; abstr TPS5623) 10.1200/JCO.2022.40.16_suppl.TPS5623

Other

Harvey, H., V. Amberger-Murphy, J. Ballot, M. O'Grady, D. O'Hare, G. Lawler, E. Bennette, M. Connolly, C. McNevin, E.Noone, M. Kelly, A. Bazin, K. Kearns, E. Mulroe, R. S. McDermott, S. O'Reilly (2022) **"Impact of Conti ransomware attack on cancer trials Ireland sites."** Publication – **ASCO 2022 - Conti ransomware attack** (suppl 16; abstr e13614) 10.1200/JCO.2022.40.16_suppl.e13614

Collins, D. C., D. Poretti, V. Murphy, M. Ganter, R. Girotti, B. H. Bird, M. Galibert, R. Dienstmann, R. S. McDermott, T. P. McVeigh, S. P. Finn (2022) **"Developing the educational molecular tumor board in Ireland: Pilot to national initiative."** Publication - **ASC0 - 2022 - Molecular Tumour Board** (suppl 16; abstr e13533) 10.1200/JCO.2022.40.16_suppl.e13533

Sendi, M. A., C. Flynn, M. R. Khan, P. Selvadurai, J. Crown, R. S. McDermott, J. M. Walshe, D. W. Fennelly, E.O. Hanrahan, M. Doherty, M. J. Higgins (2022) **"Pilot study of the implementation of G8 screening tool, cognitive screening assessment and chemotherapy toxicity assessment in older adults with cancer in a tertiary University Hospital in Ireland."** Publication - **ASCO - 2022 - Comprehensive Geriatric assessment** (suppl 16; abstr e24019) 10.1200/JCO.2022.40.16_suppl.e24019

Dennehy, C., M. Javad Ghassemi Rad, M. Kennedy, M. Henry, D. C. Collins, N. Lyons, E. O'Reilly, R. M. Connolly (2022) **"The impact of COVID-19 on the performance of the Rapid Access Lung Clinic: The Cork/Kerry experience."** Publication - **ASCO-2022-COVID-19 pandemic** (suppl 16; abstr e20542) 10.1200/JCO.2022.40.16_suppl.e20542

Fundraising:

Irish Cancer Society
The Irish Cancer Society maintained increased funding for the year to Cancer Trials Ireland, having doubled funding from €500,000 to €1m in 2021.

Fundraising in memory of Louise Creevy
Louise Creevy, who passed away in July 2021, has inspired and incredible amount of fundraising for Cancer Trials Ireland, through her family, friends and colleagues. In May 2022, Louise's colleagues in Bannon Property organises and hosted a live music event, the Property Picnic, which went on to raise more than €170,000. Meanwhile, the colleagues of Louise's husband in Nestle chose Cancer Trials Ireland as their staff charity, donating almost €7,000 in the year. Particular thanks to Jim Giles for his personal effort on cycling the length of the country on our behalf.

Pancreatic
The work of Pat Smullen and his family, friends, and the horse racing community in 2019 put Cancer Trials Ireland on the fundraising map, linking the organisation with pancreatic trials research in the minds of the public. In 2022, the Coast to Curragh cycle teamed up with The Curragh and Frances Smullen to host the Pat Smullen Race Day in August. The event raised €167,000 for pancreatic cancer trials and associated initiatives. This fantastic donation was augmented with the news that The Curragh and the Committee for the Pat Smullen Race Day were committed to hosting the event for the coming few years. Meanwhile, Noel Connellan raised €5,715 in April.

Gastrointestinal
As in previous years, the Oesophageal Cancer Fund organised a charity walk to raise money to support the NeoAEGIS trial. Their target was €50,000, which they more than met. Thanks also to the CTI staff members who took part themselves.

Breast
A private, Irish-based donor organisation, delivered a second instalment of €30,000 for breast cancer research (having already donated €30,000 in 2021) Once again, Cancer Trials Ireland is extremely grateful for the donations and we will keep our membership informed on decisions about how this money is allocated to breast cancer trials research.

Ovarian - Friends of Cancer Trials Ireland
After a few years absence due to the pandemic, the Friends of Cancer Trials Ireland once again hosted their gala lunch event in November, which raised €141,000 for ovarian cancer trials and research in 2022. Huge thanks to the organising committee for this event.

Other
- Cancer Trials Ireland was bequeathed 30,000 from a donor in Co Monaghan.
- Donegal Shines a light raised a further €250 for lung cancer research in 2022, having raised over €1,000 the previous year.
- The Edmondstown Golf Club, which counts Cancer Trials Ireland Board Member Rory Montgomery among its members, raised €7,313 for Cancer Trials Ireland.
- Aisling Gannon & Brian McKeon raise €3,920 in the latter part of 2022.
- The Templeogue Tennis Club raised €2,084
- David Kelly hosted a darts event in Blanchardstown in 2022 raising €820.


Statement of income & retained earnings for the financial year ended 31 December 2022

	Notes	2022 €	2021 €
Income	4	3,958,709	3,955,641
Expenditure		(4,380,850)	(4,030,826)
Deficit on ordinary activities before interest		(422,141)	(75,185)
Interest receivable and similar income	5	1,005	342
DEFICIT FOR THE FINANCIAL YEAR	6	(421,136)	(74,843)
RETAINED EARNINGS AT THE BEGINNING OF THE FINANCIAL YEAR		884,832	959,675
RETAINED EARNINGS AT THE END OF THE FINANCIAL YEAR		463,696	884,832

Balance Sheet as at 31 December 2022

	Notes	2022 €	2021 €
Fixed Assets			
Tangible assets	10	120,003	127,157
Current Assets			
Debtors	11	1,893,543	1,840,174
Cash and cash equivalents		4,298,305	6,243,973
		6,191,848	8,084,147
Creditors: Amounts falling due within one year	12	(5,848,155)	(7,326,472)
Net Current Assets		343,693	757,675
Net Assets		463,696	884,832
Reserves			
Retained earnings		463,696	884,832
		463,696	884,832

The financial statements were approved and authorised for issue by the Board of Directors on 28 August 2023 and signed on its behalf by:



Rory Montgomery
Director



Deirdre Somers
Director & Chairperson

*Full copy of financial statements for 2022 at www.cancertrials.ie

cancer trials ireland

Together, we're finding answers to cancer.

© September 2023

Cancer Trials Ireland is supported by:

Irish Cancer Society

HRB Health Research Board